SCHEMBL4555367

SCHEMBL4555367

CCCC(C)c1ccccc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
TSHR P16473 1/20 0.41
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP3A4 P08684 2/20 0.36
ALOX15 P16050 2/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
TAAR1 Q96RJ0 2/20 0.34
AOC3 Q16853 2/20 0.34
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
FFAR1 O14842 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
HDAC3 O15379 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11035218 0.88 CYP1A2 (0.43) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL3995524 0.86 CYP1A2 (0.42) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL9355947 0.85 CYP1A2 (0.41) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL20921378 0.85 CYP1A2 (0.41) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL21081220 0.85 TSHR (0.40) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL16294616 0.85 CYP1A2 (0.41) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL31380293 0.84 TSHR (0.48) TSHRCYP1A2SMN1; SMN2CYP3A4TAAR1
SCHEMBL10694822 0.83 HRH1 (0.40) ALDH1A1TSHRSMN1; SMN2CYP3A4ALOX15
SCHEMBL2386784 0.83 ALDH1A1 (0.36) ALDH1A1TSHRSMN1; SMN2CYP3A4ALOX15
SCHEMBL3820403 0.83 TSHR (0.59) ALDH1A1TSHRCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731689-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE Covestro Deutschland AG (DE) 2026-04-29 EP disclosed
EP-4200351-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 EP disclosed
EP-4448605-B1 PROCESS FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 EP disclosed
EP-4200353-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 EP disclosed
EP-4200352-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 EP disclosed
US-12466913-B2 Method for the production of a thermoplastic polyoxazolidinone COVESTRO DEUTSCHLAND AG (DE) 2025-11-11 US disclosed
US-12378348-B2 Method for the production of a thermoplastic polyoxazolidinone COVESTRO DEUTSCHLAND AG (DE) 2025-08-05 US disclosed
US-20250043061-A1 PROCESS FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-02-06 US disclosed
WO-2024260858-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2024-12-26 WO disclosed
EP-4448605-A1 PROCESS FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE Covestro Deutschland AG (DE) 2024-10-23 EP disclosed
WO-2018039331-A1 NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2018-03-01 WO disclosed
US-20170334893-A1 Isoxazole Analogs as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-9546174-B2 Inhibitor of apoptosis protein (IAP) antagonists SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2017-01-17 US disclosed
US-20150307499-A1 INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2015-10-29 US disclosed
US-8586611-B2 Fungicidal carboxamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 2013-11-19 US disclosed
EP-2137186-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2009-12-30 EP disclosed
WO-2008118468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2008-10-02 WO disclosed
US-5200488-A POLYORGANOSILOXANE HAVING A QUATERNARY SALT AT ITS ONE TERMINAL AND PERCUTANEOUS ABSORPTION-PROMOTING AGENT SAGAMI CHEMICAL RESEARCH CENTER (JP) 1993-04-06 US disclosed
US-4925984-A REACTION WITH BROMINE IN SOLUTION ETHYL CORPORATION (US) 1990-05-15 US disclosed
US-4194008-A INSECTICIDE, FUNGICIDE, MITICIDE, PARASITICIDES BAYER AKTIENGESELLSCHAFT (DE) 1980-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334893-A1 Isoxazole Analogs as FXR Agonists and Methods of Use Thereof FXR1, SLC10A1, NR1H4 ALDH1A1 1159/4885TSHR 819/4885CYP1A2 128/4885
US-20150307499-A1 INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS API5, XIAP, BIRC5 ALDH1A1 4556/4885TSHR 4620/4885CYP1A2 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.